PharmaKnowl Consulting participated in BIOCHINA 2026, held in Suzhou, China, one of the world’s premier platforms bringing together innovators, investors, and regulators shaping the future of the global biopharmaceutical industry.

Our CEO, Mohammed Jobran, attended the event as part of our continued efforts to strengthen cross-border collaboration and knowledge exchange with global life sciences stakeholders.

This year’s conference theme, “Fusion & Forward,” spotlighted the growing importance of innovation ecosystems and cross-border partnerships in accelerating therapeutic development, from early research and clinical translation through to large-scale manufacturing and market access.

Across the three days, forums and discussions explored next‑generation biologics, including advanced modalities such as cell and gene therapies, bispecific antibodies, and nucleic acid-based therapeutics, alongside new platform technologies enabling more efficient and scalable development. BIOCHINA 2026 also placed strong emphasis on digital transformation in pharma, highlighting the role of AI, data analytics, and automation in reshaping R&D, clinical trials, and supply chain operations, as well as on emerging regulatory trends that seek to keep pace with this innovation while safeguarding quality, safety, and patient outcomes.

At PharmaKnowl Consulting, we recognize that staying connected with global biopharma developments enables us to better support pharmaceutical, biotech, and MedTech companies navigating regulatory registration and compliance pathways in Saudi Arabia and the GCC region.

Our participation in BIOCHINA 2026 underscores PharmaKnowl’s commitment to fostering international collaboration, sharing regulatory insights, and contributing to the shared mission of transforming healthcare through science and innovation.